Home » Stem Cell Professional News » Prognosis E-News

Dr. Abidi has led a two-part Phase I dose escalation study that enrolled patients with multiple myeloma with normal and abnormal renal function. Multiple myeloma — cancer of the plasma cells — can cause kidney disease, … The drug Melphalan is the standard conditioning treatment that prepares patients for autologous stem cell transplantation. However, it brings with it symptoms that include severe mouth ulcers at doses of 200 milligrams per meter squared or higher, …
[Read more]

Comments are closed.

FREE SUBSCRIPTION

Just fill in your email address, we will send you the latest market update periodically.

Contact Us

Name*

Email*

Tel

Message*

captcha

*require